Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of symmetric IgG and composition thereof in preparing drugs for treating and preventing tumors

A composition and tumor technology, applied in the field of tumor immunotherapy drugs, can solve problems such as the launch of mature drugs

Active Publication Date: 2019-08-23
SHANTOU UNIV MEDICAL COLLEGE
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, most immunotherapy drugs are still in clinical trials or preclinical research, and there are not many mature drugs on the market.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of symmetric IgG and composition thereof in preparing drugs for treating and preventing tumors
  • Use of symmetric IgG and composition thereof in preparing drugs for treating and preventing tumors
  • Use of symmetric IgG and composition thereof in preparing drugs for treating and preventing tumors

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0046] Experimental example 1: anti-tumor effect of symmetrical IgG

[0047] Human IgG is divided into asymmetric IgG (Asy IgG) and symmetric IgG (Sy IgG) by ConA adsorption method, and purified by rProtein G, the specific method is as follows:

[0048] Human IgG flows through the ConA column by gravity, and ConA can be combined with mannose sugars to adsorb glycosylated asymmetric IgG (Asy IgG), while non-Fab glycosylated symmetrical IgG (Sy IgG) flows out The column collects concentrated non-glycosylated symmetrical IgG (Sy IgG). Wash the column with balanced salt solution to remove residual Sy IgG, then use α-methylmannose solution to competitively bind ConA, so that the glycosylated asymmetric IgG (Asy IgG) is separated from ConA, flows out of the column, and is collected and concentrated separately to obtain Asy IgG. In order to prevent residual ConA in the separated Asy IgG and Sy IgG, we pass Asy IgG and Sy IgG through the rProtein G column respectively, both Asy IgG ...

experiment example 2

[0052] Experimental Example 2: Clinical Trial

[0053] A 63-year-old male patient with advanced squamous cell carcinoma of the lung, whose disease was still not under control after surgery, radiotherapy and chemotherapy, the doctor judged that the patient's expected survival period was 3 months, the patient voluntarily used the above symmetric IgG immunotherapy, Intravenous infusion has been used for 18 months so far, the condition has not deteriorated, the patient is still alive, and no side effects have been found.

[0054] Another patient with advanced esophageal cancer (squamous cell carcinoma), a 56-year-old male, had lung metastases, and the cancer could not be controlled after radiotherapy and chemotherapy. The doctor expected the patient's survival to be less than 3 months. Under the strong request, the above immunotherapy was used through intravenous infusion. So far, the patient has survived for 15 months without any further tumor development and no side effects.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses use of symmetric IgG and composition thereof in preparing drugs for treating and preventing tumors. The symmetric IgG can widely prevent and treat various malignant tumors, thedrug cost is relatively low, the adaption diseases are wide, no obvious side effect exists, and the clinical application prospects are wide.

Description

technical field [0001] The invention belongs to the technical field of tumor immunotherapy drugs, and in particular relates to the application of symmetrical IgG and its composition in the preparation of drugs for treating and preventing tumors. Background technique [0002] The incidence of tumors in my country, especially malignant tumors, is increasing day by day, and the mortality rate remains high. There are nearly 4 million new tumors every year, and more than 2 million people die of tumors. There is an urgent need for new methods for effective prevention and treatment of tumors. The occurrence and development of tumors are caused by two factors. One is the uncontrolled growth and division of tumor cells, and the other is the failure of the body's immune function to recognize and inhibit the growth of tumor cells. [0003] The current treatment methods for cancer mainly include surgery, radiotherapy, chemotherapy, targeted therapy and immunotherapy. Radiotherapy and c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/395A61K45/06A61P35/00A61P35/04
CPCA61K39/395A61K45/06
Inventor 顾江
Owner SHANTOU UNIV MEDICAL COLLEGE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com